NIKKEI 225
38,913.48 +296.38 (+0.77%) HANG SENG
18,939.96 -255.64 (-1.33%) CRUDE OIL
77.10 -0.47 (-0.61%) GOLD FUTURES
2,372.90 -20.00 (-0.84%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,432.33 -489.04 (-0.89%)
Cogent Biosciences, Inc. (COGT)
After hours:
| Previous close | 7.92 |
| Open | 7.93 |
| Bid | 8.03 x 200 |
| Ask | 8.07 x 100 |
| Day's range | 7.91 - 8.29 |
| 52-week range | 3.67 - 13.50 |
| Volume | |
| Avg. volume | 1,502,364 |
| Market cap | 767.776M |
| Beta (5Y monthly) | -0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.52 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.70 |
Simply Wall St.We Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
GlobeNewswireCogent Biosciences Reports First Quarter 2024 Financial Results
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 1Q 2024 with $435.7 million in cash, sufficient to fund operations into 2027 WALTHAM, Mass. and BOULDER, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results
- GlobeNewswire
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
IND-enabling studies expected to begin mid-2024WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program. The data are being presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taki
